Hikma Pharmaceuticals USA Inc.

Hikma Pharmaceuticals USA Inc., doing business as FKA West-Ward Pharmaceuticals, supplies generic injectable and non-injectable pharmaceutical products to the Defense Logistics Agency and Department of Veterans Affairs as a prime contractor on full-and-open delivery orders and indefinite delivery vehicles, with no subcontract footprint in the federal space.

Hikma is a foreign-owned, for-profit pharmaceutical manufacturer headquartered in Berkeley Heights, New Jersey, operating under NAICS 325412 (Medicinal and Botanical Manufacturing) and PSC 65 (Drugs and Biologicals). The vendor does not hold SBA certifications and competes on full-and-open vehicles with no set-aside designation. Over the past five years, the source records 511 prime awards with a combined potential value of $2 billion, though only $18.4 million (1% of combined potential) has been obligated to date—a profile consistent with high-ceiling indefinite delivery vehicles and small frequent delivery orders against them.

Hikma's customer concentration is heavily weighted toward Defense Logistics Agency Troop Support Medical, which accounts for 400 awards (78% of the portfolio) with $56.7 million combined potential value, driven by routine small-dollar delivery orders for critical injectable medications including morphine sulfate, doxycycline hyclate, naloxone, ketamine, vancomycin, and ondansetron. The Department of Veterans Affairs dominates by potential value: the VA's Veterans Health Administration Veterans Integrated Service Network 12 holds 10 awards with $556.4 million combined potential, anchored by a $216 million Federal Supply Schedule contract for pharmaceuticals and drugs (FSS-61-IB) awarded August 15, 2021, with an August 14, 2026 expiration. The VA's National Acquisition Center carries two awards worth $40.9 million combined: a $38.5 million single-award Blanket Purchase Agreement for sodium oxybate (XYREM) running through December 17, 2025, and a $2.37 million single-award Indefinite Delivery Contract for Hydralazine Hydrochloride Injections awarded January 20, 2026, extending through January 19, 2031 with four one-year renewal options.

Hikma's vehicle portfolio is anchored by two DLA Troop Support Medical indefinite delivery contracts—SPM2D007D0004 (234 task orders, $10.8 million combined potential value) and SPE2D020D0006 (163 task orders, $2.1 million combined potential value)—which collectively account for the majority of delivery-order activity. The VA Federal Supply Schedule contract (V797P5804X) carries 27 task orders with $86.3 million combined potential value. Across all vehicles, delivery orders are characterized by firm fixed-price structure, narrow performance windows (often same-day or next-day completion), and unit values ranging from under one hundred dollars for smaller quantities to over $290,000 for large vancomycin or doxycycline orders. The source indicates Hikma holds a multi-billion-dollar ceiling across its federal vehicle portfolio, positioning the vendor as a critical pharmaceutical supplier to military treatment facilities and VA healthcare networks.

Activity has been volatile: the vendor recorded 38 awards in 2022, peaked at 51 in 2023, dropped to 7 in 2024, and recovered to 29 in 2025 and 18 year-to-date in 2026. The $216 million VA Federal Supply Schedule contract and the $38.5 million sodium oxybate BPA represent recompete exposure in the next twelve to eighteen months, with the supply schedule terminating August 14, 2026.